Sanofi, As­traZeneca clinch first OK for RSV an­ti­body — just as vac­cines line up at reg­u­la­tors

The EU has of­fi­cial­ly stamped its seal of ap­proval for nir­se­vimab, the an­ti­body joint­ly de­vel­oped by Sanofi and As­traZeneca to pre­vent RSV dis­ease in in­fants.

Bey­for­tus will be the first sin­gle-dose pro­tec­tive op­tion for new­borns and in­fants dur­ing their first RSV sea­son, the com­pa­nies not­ed. While a dif­fer­ent an­ti­body, Synagis, has been on the mar­ket for two decades, it on­ly cov­ers a sub­set of in­fants at high risk of se­vere dis­ease and it has to be ad­min­is­tered month­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER